70 related articles for article (PubMed ID: 30679079)
1. Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).
Beau-Faller M; Texier M; Blons H; Richard N; Escande F; Melaabi S; Lizard S; De Fraipont F; Longchampt E; Morin F; Zalcman G; Pignon JP; Cadranel J
Clin Lung Cancer; 2019 May; 20(3):222-230. PubMed ID: 30679079
[TBL] [Abstract][Full Text] [Related]
2. STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract][Full Text] [Related]
3. Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers.
Bagnyukova T; Egleston BL; Pavlov VA; Serebriiskii IG; Golemis EA; Borghaei H
Cancer Res Commun; 2024 May; 4(5):1227-1239. PubMed ID: 38639476
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
[TBL] [Abstract][Full Text] [Related]
5. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
Shepherd FA; Lacas B; Le Teuff G; Hainaut P; Jänne PA; Pignon JP; Le Chevalier T; Seymour L; Douillard JY; Graziano S; Brambilla E; Pirker R; Filipits M; Kratzke R; Soria JC; Tsao MS;
J Clin Oncol; 2017 Jun; 35(18):2018-2027. PubMed ID: 28453411
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Chaft JE; Dagogo-Jack I; Santini FC; Eng J; Yeap BY; Izar B; Chin E; Jones DR; Kris MG; Shaw AT; Gainor JF
Lung Cancer; 2018 Aug; 122():67-71. PubMed ID: 30032847
[TBL] [Abstract][Full Text] [Related]
7. Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Patel SH; Rimner A; Foster A; Zhang Z; Woo KM; Yu HA; Riely GJ; Wu AJ
Lung Cancer; 2017 Jun; 108():109-114. PubMed ID: 28625621
[TBL] [Abstract][Full Text] [Related]
8. NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer.
Moisés J; Navarro A; Santasusagna S; Viñolas N; Molins L; Ramirez J; Osorio J; Saco A; Castellano JJ; Muñoz C; Morales S; Monzó M; Marrades RM
BMC Pulm Med; 2017 Dec; 17(1):197. PubMed ID: 29237428
[TBL] [Abstract][Full Text] [Related]
9. The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order.
Xie G; Xie F; Wu P; Yuan X; Ma Y; Xu Y; Li L; Xu L; Yang M; Shen L
J Exp Clin Cancer Res; 2015 Jun; 34(1):63. PubMed ID: 26081767
[TBL] [Abstract][Full Text] [Related]
10. Targeting
Uras IZ; Moll HP; Casanova E
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
[TBL] [Abstract][Full Text] [Related]
11. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M
Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner.
Kiss E; Abdelwahab EHMM; Steib A; Papp E; Torok Z; Jakab L; Smuk G; Sarosi V; Pongracz JE
Respir Res; 2020 May; 21(1):120. PubMed ID: 32434541
[TBL] [Abstract][Full Text] [Related]
13. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with
Drilon A; Schoenfeld AJ; Arbour KC; Litvak A; Ni A; Montecalvo J; Yu HA; Panora E; Ahn L; Kennedy M; Haughney-Siller A; Miller V; Ginsberg M; Ladanyi M; Arcila M; Rekhtman N; Kris MG; Riely GJ
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936194
[No Abstract] [Full Text] [Related]
14. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Immunotherapy in Second-Line Treatment of
Knetki-Wróblewska M; Tabor S; Płużański A; Lewandowska Z; Tysarowski A; Pawlik H; Kowalski DM; Krzakowski M
Curr Oncol; 2022 Dec; 30(1):462-475. PubMed ID: 36661686
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Shin DH; Jo JY; Choi M; Kim KH; Bae YK; Kim SS
Exp Mol Med; 2023 Oct; 55(10):2220-2237. PubMed ID: 37779142
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence Study of Patients with
Anttalainen A; Pietarinen P; Tuominen S; Mattila R; Mutka A; Knuuttila A
Curr Oncol; 2024 May; 31(5):2700-2712. PubMed ID: 38785486
[TBL] [Abstract][Full Text] [Related]
18. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.
Shen Z; Teng M; Han L; Bian D; Zhang J; Zhu X; Qing Y; Hu S; Chen Y; Yao W; Yu H; Zhang L; Zhang P
Cancer Immunol Immunother; 2023 Dec; 72(12):4235-4247. PubMed ID: 37932425
[TBL] [Abstract][Full Text] [Related]
19. Response to first-line pembrolizumab in metastatic
Rossi S; Pagliaro A; Finocchiaro G; Marinello A; Giordano L; Bria E; Stefani A; Vitale A; Toschi L; D'Argento E; Santoro A
Future Oncol; 2024 Mar; 20(7):373-380. PubMed ID: 38445372
[No Abstract] [Full Text] [Related]
20. Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS.
Pinheiro G; Pereira T; Dias C; Freitas C; Hespanhol V; Costa JL; Cunha A; Oliveira HP
Sci Rep; 2020 Feb; 10(1):3625. PubMed ID: 32107398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
